241 related articles for article (PubMed ID: 22447839)
1. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
[TBL] [Abstract][Full Text] [Related]
2. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
[TBL] [Abstract][Full Text] [Related]
3. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
6. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
7. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
8. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
Kari EJM; Kuusisto MEL; Honkavaara P; Hakalahti A; Haapasaari KM; Bloigu R; Karihtala P; Teppo HR; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2020 Aug; 105(2):156-163. PubMed ID: 32248578
[TBL] [Abstract][Full Text] [Related]
10. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
11. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
[TBL] [Abstract][Full Text] [Related]
12. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract][Full Text] [Related]
13. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
15. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
[TBL] [Abstract][Full Text] [Related]
18. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
[TBL] [Abstract][Full Text] [Related]
19. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Meng H; Zhao B; Wang Y
Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
